Thursday, July 28, 2016

Phase III tau drug fails to meet endpoints but shows silver lining as monotherapy

At AAIC2016, researchers from TauRx Therapeutics Ltd presented results from a phase III clinical trial of the drug leuco-methylthioninium-bis(hydromethanesulfonate) or LMTM in people with mild-to-moderate Alzheimer’s disease.

from Dementia Big http://ift.tt/2afT7DZ via alcoholic dementia


http://ift.tt/2aztHXq
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)